Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations (GLP-1 and GIP), stimulating glucose-dependent insulin release and decreasing glucagon secretion. It is distinguished by its primary biliary excretion route.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (under 18 years) have not been established. Use is generally not recommended in this population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for patients with renal impairment, including end-stage renal disease (ESRD).
* **Hepatic Impairment:** No dose adjustment is required for patients with hepatic impairment.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis, increased uric acid, hyperlipidemia.
* **Serious:** Acute pancreatitis (discontinue if suspected), bullous pemphigoid, severe arthralgia, hypersensitivity reactions (urticaria, angioedema), and hypoglycemia (when used with insulin or secretagogues).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Insulin Secretagogues (e.g., sulfonylureas):** Increased risk of hypoglycemia; a reduction in the dose of the insulin or secretagogue may be required.
## Monitoring
* **Glycemic Control:** A1C (typically every 3–6 months) and self-monitoring of blood glucose (SMBG).
* **Symptoms:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and worsening skin lesions (bullous pemphigoid).
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustment, making it a convenient choice for patients with chronic kidney disease.
* It is weight-neutral and carries a low intrinsic risk of hypoglycemia when used as monotherapy.
* Administration is independent of meals.
* If a dose is missed, take it as soon as remembered, but do not take two doses on the same day.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols may vary. Always verify current prescribing information, contraindications, and drug interaction databases (e.g., Lexicomp, Micromedex, or package inserts) before prescribing or administering medication.
